Solid Biosciences Inc. Segments Disclosure
15. Segment Reporting
The Company has one reportable and one operating segment and conducts its business activities primarily in North America and on a consolidated basis. The Company’s singular focus is developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. All of the Company’s tangible assets are held in the United States.
The accounting policies of the Company are the same as those described in the summary of significant accounting policies.
The Company’s chief operating decision maker (“CODM”) is its . The CODM assesses performance for the Company and decides how to allocate resources based on net loss as reported on the consolidated statements of operations. The annual budgeting process is the primary mechanism used to make these decisions. The financial information also helps in making performance assessments using budgeted versus actual results.
The following table presents segment expenses, other segment items, and segment net loss for the periods presented:
|
|
Year Ended |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Segment expenses: |
|
|
|
|
|
|
||
SGT-003 |
|
|
58,340 |
|
|
|
15,197 |
|
SGT-501 |
|
|
9,641 |
|
|
|
17,223 |
|
External R&D other |
|
|
10,649 |
|
|
|
10,580 |
|
Internal R&D expense(1) |
|
|
29,335 |
|
|
|
21,705 |
|
External G&A expense |
|
|
19,469 |
|
|
|
20,122 |
|
Internal G&A expense(1) |
|
|
13,956 |
|
|
|
12,223 |
|
Other segment items(2) |
|
|
37,816 |
|
|
|
32,678 |
|
Other income, net |
|
|
(4,881 |
) |
|
|
(5,031 |
) |
Consolidated net loss |
|
|
(174,325 |
) |
|
|
(124,697 |
) |
(1) |
Internal expenses consisted primarily of payroll and related costs, temporary services, and travel and entertainment. |
(2) |
Other segment items primarily included other program costs, equity-based compensation expense, and depreciation and amortization expense. |
The measure of segment assets is reported on the balance sheet as total consolidated assets.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 19, 2026 | Showing above |
| 2024 | Mar 6, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.